Reirradiation to the pelvis for recurrent rectal cancer.
OBJECTIVE
This study investigated late toxicity and infield progression-free survival in patients with locally recurrent rectal cancer (LRRC) who had previously received irradiation to the pelvis.


METHODS
Twenty-two patients were treated by reirradiation to the pelvis between January 2000 and August 2007. All patients received curative surgery with preoperative or postoperative chemoradiotherapy as an initial treatment. Five patients (23%) underwent surgical resection after reirradiation. The median follow-up duration was 20 months (range, 7-91 months).


RESULTS
Two patients (9%) had grade-3 acute toxicity and eight patients (36%) had grade-3 to -4 late toxicity. The incidence of grade-3 to -4 late toxicity in the gastrointestinal and urinary system was 18% and 27%, respectively. Recurrent tumor location (axial or anterior) and surgical resection after reirradiation significantly influenced severe late toxicity (P = 0.024 and P = 0.039, respectively). In the 17 patients not undergoing surgery after reirradiation, median infield progression-free survival was 16 months. Reirradiation doses exceeding 50 Gy(αβ10) (equivalent dose in 2 Gy fractions) significantly increased the infield progression-free survival (P = 0.005).


CONCLUSIONS
Tumor location (axial or anterior) and surgery after reirradiation may increase severe late toxicity. In addition, an EQD2 exceeding 50 Gy(αβ10) may improve infield control.
Department of Radiation Oncology, Yonsei Colorectal Cancer Clinic, Yonsei University College of Medicine, Seoul, South Korea.
Woong Sub
WS
Koom
Yunseon
Y
Choi
Su Jung
SJ
Shim
Jihye
J
Cha
Jinsil
J
Seong
Nam Kyu
NK
Kim
Ki Chang
KC
Nam
Ki Chang
KC
Keum
D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000532:radiotherapy*; D010388:Pelvis / Q000528:radiation effects*; D011878:Radiotherapy / Q000009:adverse effects; D012004:Rectal Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D015996:Survival Rate